ALLIANCES AND COLLABORATIONS (Tables)

12 Months Ended

Dec. 31, 2011

Sanofi [Member]

Alliances and Collaborations Statement [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

		Year Ended December 31,
Dollars in Millions		2011			2010		2009
Territory covering the Americas and Australia:
	Net sales	$	7,761	$	7,464	$	6,912
	Royalty expense		1,583		1,527		1,404
	Noncontrolling interest – pre-tax		2,323		2,074		1,717
	Profit distributions to Sanofi		(2,335)		(2,093)		(1,717)
Territory covering Europe and Asia:
	Equity in net income of affiliates		(298)		(325)		(558)
	Profit distributions to BMS		283		313		554
Other:
	Net sales in Europe comarketing countries and other		279		378		517
	Amortization (income)/expense – irbesartan license fee		(31)		(31)		(32)
	Supply activities and development and opt-out royalty (income)/expense		23		(3)		(41)
				December 31,
Dollars in Millions					2011		2010
Investment in affiliates – territory covering Europe and Asia				$	37	$	22
Deferred income – irbesartan license fee					29		60

Sanofi [Member] | Territory Covering Europe and Asia [Member]

Alliances and Collaborations Statement [Line Items]

Equity Method Investments Disclosure [Text Block]

	Year Ended December 31,
Dollars in Millions	2011		2010		2009
Net sales	$	1,469	$	1,879	$	2,984
Cost of products sold		811		1,047		1,510
Gross profit		658		832		1,474
Marketing, selling and administrative		75		129		219
Advertising and product promotion		15		29		68
Research and development		5		16		61
Other (income)/expense		1		(1)		-
Net income	$	562	$	659	$	1,126
Current assets	$	584	$	751	$	1,305
Current liabilities		584		751		1,305

Otsuka [Member]

Alliances and Collaborations Statement [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

	Year Ended December 31,
Dollars in Millions	2011		2010		2009
ABILIFY* net sales, including amortization of extension payment	$	2,758	$	2,565	$	2,592
Oncology Products collaboration fee expense		134		128		-
Royalty expense		72		62		58
Reimbursement of operating expenses to/(from) Otsuka		(88)		(101)		-
Amortization (income)/expense – extension payment		66		66		49
Amortization (income)/expense – upfront, milestone and other licensing payments		6		6		6
			December 31,
Dollars in Millions			2011		2010
Other assets – extension payment			$	219	$	285
Other intangible assets – upfront, milestone and other licensing payments				5		11

Schedule Of Percentage Of Net Sales Recognized From Collaboration

	Share as a % of U.S. Net
	Sales
$0 to $2.7 billion	50%
$2.7 billion to $3.2 billion	20%
$3.2 billion to $3.7 billion	7%
$3.7 billion to $4.0 billion	2%
$4.0 billion to $4.2 billion	1%
In excess of $4.2 billion	20%

Schedule Of Percentage Of Net Sales Payable As Collaboration Fee

	% of Net Sales
	2010 - 2012	2013 - 2020
$0 to $400 million	30%	65%
$400 million to $600 million	5%	12%
$600 million to $800 million	3%	3%
$800 million to $1.0 billion	2%	2%
In excess of $1.0 billion	1%	1%

Lilly [Member]

Alliances and Collaborations Statement [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

	Year Ended December 31,
Dollars in Millions	2011		2010		2009
Net sales	$	691	$	662	$	683
Distribution fees and royalty expense		287		275		279
Research and development expense reimbursement to Lilly - necitumumab		12		12		5
Amortization (income)/expense – upfront, milestone and other licensing payments		37		37		37
Japan commercialization fee (income)/expense		(34)		(39)		(28)
			December 31,
Dollars in Millions			2011		2010
Other intangible assets – upfront, milestone and other licensing payments			$	249	$	286

Gilead [Member]

Alliances and Collaborations Statement [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

	Year Ended December 31,
Dollars in Millions	2011		2010		2009
Net sales	$	1,204	$	1,053	$	869
Equity in net loss of affiliates		16		12		10

AstraZeneca [Member]

Alliances and Collaborations Statement [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

		Year Ended December 31,
Dollars in Millions		2011		2010		2009
Net sales		$	473	$	158	$	24
Profit sharing expense			207		67		11
Commercialization expense reimbursements to/(from) AstraZeneca			(40)		(33)		(15)
Research and development expense reimbursements to/(from) AstraZeneca			40		19		(38)
Amortization (income)/expense – upfront, milestone and other licensing payments			(38)		(28)		(16)
Upfront, milestone and other licensing payments received
	Saxagliptin		-		50		150
	Dapagliflozin		120		-		-
				December 31,
Dollars in Millions				2011		2010
Deferred income – upfront, milestone and other licensing payments
	Saxagliptin			$	230	$	254
	Dapagliflozin				142		36

Pfizer [Member]

Alliances and Collaborations Statement [Line Items]

Summarized Financial Information Reflected In Consolidated Financial Statements [Text Block]

	Year Ended December 31,
Dollars in Millions	2011		2010		2009
Commercialization expense reimbursements to/(from) Pfizer	$	(10)	$	(8)	$	1
Research and development reimbursements to/(from) Pfizer		(65)		(190)		(190)
Amortization (income)/expense – upfront, milestone and other licensing payments		(33)		(31)		(28)
Upfront, milestone and other licensing payments received		65		10		150
			December 31,
Dollars in Millions			2011		2010
Deferred income – upfront, milestone and other licensing payments			$	434	$	382